Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
ANIP Stock Forecast 2025-2026
$69.82
Current Price
$1.51B
Market Cap
Buy 7
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to ANIP Price Targets
+34.6%
To High Target of $94.00
+18.9%
To Median Target of $83.00
-6.9%
To Low Target of $65.00
ANIP Price Momentum
+2.7%
1 Week Change
+3.3%
1 Month Change
+6.8%
1 Year Change
+26.3%
Year-to-Date Change
-1.0%
From 52W High of $70.55
+33.0%
From 52W Low of $52.50
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching ANI Pharmaceuticals (ANIP) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on ANIP and similar high-potential opportunities.
Latest ANIP Stock Price Targets & Analyst Predictions
Based on our analysis of 12 Wall Street analysts, ANIP has a bullish consensus with a median price target of $83.00 (ranging from $65.00 to $94.00). The overall analyst rating is Strong Buy (8.5/10). Currently trading at $69.82, the median forecast implies a 18.9% upside. This outlook is supported by 7 Buy, 1 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Oren Livnat at HC Wainwright & Co., projecting a 34.6% upside. Conversely, the most conservative target is provided by Gregory Fraser at Truist Securities, suggesting a 6.9% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ANIP Analyst Ratings
7
Buy
1
Hold
0
Sell
ANIP Price Target Range
Low
$65.00
Average
$83.00
High
$94.00
Current: $69.82
Latest ANIP Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ANIP.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 21, 2025 | Truist Securities | Gregory Fraser | Hold | Maintains | $65.00 |
| Apr 11, 2025 | Guggenheim | Vamil Divan | Buy | Reiterates | $86.00 |
| Mar 17, 2025 | HC Wainwright & Co. | Oren Livnat | Buy | Reiterates | $94.00 |
| Mar 14, 2025 | Jefferies | Glen Santangelo | Buy | Initiates | $80.00 |
| Mar 12, 2025 | JP Morgan | Ekaterina Knyazkova | Overweight | Initiates | $85.00 |
| Mar 5, 2025 | Guggenheim | Vamil Divan | Buy | Maintains | $86.00 |
| Mar 3, 2025 | HC Wainwright & Co. | Oren Livnat | Buy | Reiterates | $94.00 |
| Dec 11, 2024 | Leerink Partners | Faisal Khurshid | Outperform | Initiates | $80.00 |
| Nov 11, 2024 | HC Wainwright & Co. | Oren Livnat | Buy | Reiterates | $94.00 |
| Oct 22, 2024 | Truist Securities | Gregory Fraser | Hold | Maintains | $62.00 |
| Oct 11, 2024 | Piper Sandler | David Amsellem | Overweight | Initiates | $68.00 |
| Sep 18, 2024 | Raymond James | Elliot Wilbur | Outperform | Maintains | $83.00 |
| Sep 17, 2024 | HC Wainwright & Co. | Oren Livnat | Buy | Reiterates | $94.00 |
| Sep 11, 2024 | Truist Securities | Gregory Fraser | Hold | Downgrade | $60.00 |
| Aug 7, 2024 | HC Wainwright & Co. | Oren Livnat | Buy | Reiterates | $94.00 |
| Jun 26, 2024 | HC Wainwright & Co. | Oren Livnat | Buy | Maintains | $94.00 |
| May 13, 2024 | HC Wainwright & Co. | Oren Livnat | Buy | Maintains | $87.00 |
| Apr 23, 2024 | Guggenheim | Vamil Divan | Buy | Reiterates | $77.00 |
| Mar 15, 2024 | Capital One | Timothy Chiang | Overweight | Initiates | $0.00 |
| Mar 5, 2024 | Guggenheim | Vamil Divan | Buy | Maintains | $77.00 |
Ani Pharmaceuticals Inc. (ANIP) Competitors
The following stocks are similar to ANI Pharmaceuticals based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
ANIP
ANI Pharmaceuticals
mkt cap
1.50B
Ani Pharmaceuticals Inc. (ANIP) Financial Data
Ani Pharmaceuticals Inc. has a market capitalization of $1.51B with a P/E ratio of 51.6x. The company generates $614.38M in trailing twelve-month revenue with a -3.0% profit margin.
Revenue growth is +44.8% quarter-over-quarter, while maintaining an operating margin of +0.8% and return on equity of -4.2%.
Valuation Metrics
Market Cap
$1.51B
Enterprise Value
$1.92B
P/E Ratio
51.6x
PEG Ratio
12.6x
Price/Sales
2.5x
Growth & Margins
Revenue Growth (YoY)
+44.8%
Gross Margin
+57.9%
Operating Margin
+0.8%
Net Margin
-3.0%
EPS Growth
+44.8%
Financial Health
Cash/Price Ratio
+10.7%
Current Ratio
2.7x
Debt/Equity
147.2x
ROE
-4.2%
ROA
+0.8%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Ani Pharmaceuticals Inc. (ANIP) Business Model
About Ani Pharmaceuticals Inc.
What They Do
Develops and markets generic and branded pharmaceuticals.
Business Model
Ani Pharmaceuticals generates revenue by developing, manufacturing, and marketing both generic and branded pharmaceutical products. The company focuses on niche markets within the healthcare sector, which allows it to provide cost-effective alternatives to expensive treatments, thereby meeting specialized medical needs.
Additional Information
With a strong emphasis on product development, Ani Pharmaceuticals operates manufacturing facilities in the United States and is actively engaged in strategic acquisitions and partnerships to enhance its market presence. The company's portfolio includes products in critical therapeutic areas such as endocrinology, oncology, and dermatology.
Company Information
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
897
CEO
Mr. Nikhil Lalwani
Country
United States
IPO Year
2000
Website
www.anipharmaceuticals.comAni Pharmaceuticals Inc. (ANIP) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
3 Reasons Growth Investors Will Love ANI (ANIP)
ANI (ANIP) could produce exceptional returns because of its solid growth attributes.
Apr 25, 2025
By Zacks Equity Research
Tale of the Tape
GILD Down on Q1 Earnings and Sales Miss, Oncology Sales Decline
Gilead Sciences' Q1 earnings and sales miss estimates on lower oncology drug sales. The stock is trading down.
Apr 25, 2025
By Zacks Equity Research
Analyst Blog
Merck Q1 Earnings & Sales Beat Estimates, '25 EPS Outlook Cut
MRK posts better-than-expected first-quarter results but trims its 2025 EPS outlook due to anticipated one-time charges.
Apr 24, 2025
By Zacks Equity Research
Analyst Blog
Latest News
Quick Summary
ANI Pharmaceuticals (ANIP) and Agenus (AGEN) have shown performance metrics against their sector benchmarks in 2023, indicating their standing in the market.
Why It Matters
Comparative performance of ANI Pharmaceuticals and Agenus against their sector indicates market positioning, investor sentiment, and potential future returns, influencing investment decisions.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
ANI (ANIP) is expected to deliver strong returns due to its solid growth potential.
Why It Matters
ANI's strong growth attributes suggest potential for high returns, signaling a favorable investment opportunity and possibly driving stock demand and price appreciation.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Investors are focusing on stocks with strong price momentum, including HRTG, MRX, KINS, ANIP, and HCI.
Why It Matters
Bullish stocks like HRTG, MRX, KINS, ANIP, and HCI indicate market confidence, potentially leading to increased demand and higher returns for investors.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
In a volatile market, it is recommended to invest in low-beta stocks. ANI Pharmaceuticals, Stride, 908 Devices, and Contango are identified as strong candidates.
Why It Matters
Low-beta stocks like ANI Pharmaceuticals, Stride, 908 Devices, and Contango can provide stability and potential gains in a volatile market, appealing to risk-averse investors.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Investors are focusing on bullish stocks such as ANIP, HRTG, AVA, and EXC, which are showing strong price momentum expected to continue.
Why It Matters
Rising stocks like ANIP, HRTG, AVA, and EXC indicate strong market momentum, suggesting potential for further gains and attracting investor interest.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
ANI Pharmaceuticals (ANIP) is currently at a 52-week high, prompting an analysis of its fundamentals to assess potential for future gains.
Why It Matters
ANI reaching a 52-week high suggests strong performance and investor confidence. Analyzing fundamentals will indicate potential for further growth or risk of a pullback.
Source: Zacks Investment Research
Market Sentiment:
Positive
Frequently Asked Questions About ANIP Stock
What is Ani Pharmaceuticals Inc.'s (ANIP) stock forecast for 2025?
Based on our analysis of 12 Wall Street analysts, Ani Pharmaceuticals Inc. (ANIP) has a median price target of $83.00. The highest price target is $94.00 and the lowest is $65.00.
Is ANIP stock a good investment in 2025?
According to current analyst ratings, ANIP has 7 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $69.82. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ANIP stock?
Wall Street analysts predict ANIP stock could reach $83.00 in the next 12 months. This represents a 18.9% increase from the current price of $69.82. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Ani Pharmaceuticals Inc.'s business model?
Ani Pharmaceuticals generates revenue by developing, manufacturing, and marketing both generic and branded pharmaceutical products. The company focuses on niche markets within the healthcare sector, which allows it to provide cost-effective alternatives to expensive treatments, thereby meeting specialized medical needs.
What is the highest forecasted price for ANIP Ani Pharmaceuticals Inc.?
The highest price target for ANIP is $94.00 from Oren Livnat at HC Wainwright & Co., which represents a 34.6% increase from the current price of $69.82.
What is the lowest forecasted price for ANIP Ani Pharmaceuticals Inc.?
The lowest price target for ANIP is $65.00 from Gregory Fraser at Truist Securities, which represents a -6.9% decrease from the current price of $69.82.
What is the overall ANIP consensus from analysts for Ani Pharmaceuticals Inc.?
The overall analyst consensus for ANIP is bullish. Out of 12 Wall Street analysts, 7 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $83.00.
How accurate are ANIP stock price projections?
Stock price projections, including those for Ani Pharmaceuticals Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 28, 2025 10:05 AM UTC